LONDON, March 9 /PRNewswire-FirstCall/ -- SkyePharma PLC announces the results of the voting at the Extraordinary General Meeting held today. The resolution considered by the meeting was the appointment of Mr Robert Thian as a director. The resolution was rejected by a significant proportion of both votes and number of shareholders.
The resolution to appoint Mr Thian as a director was defeated by a majority of 28.5 million shares
For the resolution: 225,843,014 votes (880 shareholders)
Against the resolution: 254,377,799 votes (2984 shareholders)
In terms of votes cast, 53% of votes were against the resolution and 47% were for the resolution. In terms of the number of shareholders voting, 23% voted for the resolution and 77% against.
Dr Jerry Karabelas, SkyePharma’s Non-Executive Chairman, said: “The EGM is now behind us. We can now get on with running the business for the benefit of all shareholders.”
For further information please contact: SkyePharma PLC +44 207 491 1777 Frank Condella, Chief Executive Officer Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world- leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma’s technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www.skyepharma.com.
Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements based upon a number of factors, which are described in SkyePharma’s 20-F and other documents on file with the SEC. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include, without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma’s ability to manufacture products on a large scale or at all, risks related to SkyePharma’s and its marketing partners’ ability to market products on a large scale to maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma’s ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.
SkyePharma PLC
CONTACT: Frank Condella, Chief Executive Officer, +44-207-491-1777, orPeter Laing, Director of Corporate Communications +44-207-491-5124, orSandra Haughton, US Investor Relations +1-212-753-5780, all of SkyePharmaPLC; Tim Anderson or Mark Court, both of Buchanan Communications+44-207-466-5000
Web site: http://www.skyepharma.com/
